

PACIFIC DIAGNOSTIC LABORATORIES
PDC (Outreach Lab Only)
Antimicrobial Susceptibility Profile January – December 2019
Percent Susceptible¹

ORGANISM ¹	AVG. SAMPLE SIZE	AMPICILLIN	AMP / SUL	NAFCIL / OXACIL	PIP / TAZO	TETRACYCLINE	CEFAZOLIN	CEFTRIAXONE	CEFTAZIDIME	CEFEPIME	CIPROFLOXACIN	LEVOFLOXACIN	GENTAMICIN	IMIPENEM	ERTAPENEM	TRIMETH / SULFA	NITROFURAN (3)	CLINDAMYCIN	ERYTHROMYCIN	VANCOMYCIN	LINEZOLID	RIFAMPIN (4)	MEROPENEM
<i>Escherichia coli</i> (all)	10385	58	64		97		88	93	93	99	83	84	91	100	100	76	96						100
<i>Escherichia coli</i> ESBL ⁷ (all)	686	0	0		91		0	0	0	84	31	30	62	98	99	48	87						100
<i>Escherichia coli</i> (Urines)	10020	62	68		97		93	99	99	99	87	88	92	99	99	77	96						
<i>Escherichia coli</i> ESBL ⁷ (Urines)	650	0	0		91		0	0	0	85	32	31	63	98	99	48	86						100
<i>Klebsiella pneumoniae</i>	1646		84		97		92	94	94	99	97	98	97	100	100	91	30						98
<i>Klebsiella oxytoca</i>	286		57		93		72	91	92	99	98	98	95	100	100	89	77						100
<i>Klebsiella sp.</i> ESBL ⁷	118		0		71		0	0	0	91	77	86	64	98	99	36	18						100
<i>Pseudomonas aeruginosa</i>	1017				90				93		98	83	94	93									84
<i>Stenotrophomonas maltophilia</i>	72											81				95							
<i>Enterobacter aerogenes</i>	253				87			88	88	99	99	98	99	58	99	99	10						100
<i>Enterobacter cloacae</i> complex	309				82			80	82	95	99	99	99	88	98	94	35						100
<i>Proteus mirabilis</i>	813	86	92		100		94	98	98	100	89	92	94	13	100	82							100
<i>Citrobacter freundii</i> complex	164							76	77	98	98	96	93	93	100	85	96						100
<i>Citrobacter koseri</i> (diversus)	228				99		98	99	99	100	100	100	100	100	100	99	89						100
<i>Serratia marcescens</i>	149				90			95	97	97	96	96	100	80	99	97							92
<i>Haemophilus influenza</i>	4	75						100			100												100
<i>Staphylococcus aureus</i>	3613			69		90	(2)				67	68	97			97	99	78	53	100	100	99	
<i>Staphylococcus aureus</i> (MSSA)	2484			100		93	(2)				87	89	99			98	99	81	70	100	100	99	
<i>Staphylococcus aureus</i> (MRSA)	1129			0		83	(2)				20	21	92			94	98	72	16	100	100	97	
<i>Enterococcus spp.</i>	1510	97									86	87 ⁵					95			98	99		
<i>Enterococcus faecalis</i>	1163	99									88	89 ⁵					98			99	99		
<i>Enterococcus faecalis</i> (VRE)	7	100									14	14				100				0	100		
<i>Enterococcus faecium</i>	62	42									40	39 ⁵					19			68	100		
<i>Enterococcus faecium</i> (VRE)	20	0									0	0					5			0	100		
Coagulase Negative Staph.	436			55		82	(2)				68	69 ⁶				74	98	71	50	100	100		
<i>Streptococcus pneumoniae</i>	95			100								96				58		90	69	100			

Footnotes:

1. Profiles include data from disk diffusion, automated testing and gradient diffusion MIC. Intermediate results have been interpreted as resistant for this tabulation. All isolates were not tested against each antibiotic in the profile.
2. Refer to oxacillin results. Oxacillin resistant strains may not respond to beta lactam antibiotics such as penicillins, cephalosporins, and imipenem.
3. Data apply only to organisms isolated from urinary tract.
4. Rifampin should not be used as a sole agent for antimicrobial therapy.
5. Fluoroquinolones are generally not an appropriate therapy against enterococcus infections from sites other than urine.
6. Staphylococcus isolates may become resistant to fluoroquinolones within 3-4 days after initiation of therapy. (CLSI M100-Ed 2, 2019)
7. ESBL rate

	2018	2019
<i>E. coli</i>	6.0%	6.6%
<i>Klebsiella sp.</i>	4.9%	6.1%

**PACIFIC DIAGNOSTIC LABORATORIES
SANTA BARBARA, CA
ANTIBIOTIC SUSCEPTIBILITY PROFILES
2019**

PDL Out Patients only

DEPARTMENT OF MICROBIOLOGY

**DR. STEWART COMER,
MEDICAL DIRECTOR
SCOMER@SBCH.ORG
(805) 569-7367**

**JANE CHOE,
MICROBIOLOGY MANAGER
JCHOE@SBCH.ORG
(805) 324-9813**